

Drug Induced Lymphadenopathy

Dr. Ankita Chouksey, Dr. H.G Varudkar, Dr. Arti Julka, Dr. Mustafa
Singapurwala, Dr. Nipun Agrawal, Dr. Ravi Shankar Mishra

Introduction: Many a times lymphadenopathy is misdiagnosed as tubercular but there is more into it. We report one such case where a wrongly diagnosed lymphadenopathy revealed itself in a different way.

Case Description: An 18 year old female presented with bilateral swelling in cervical region (fig 1), dry cough, fever and reduced appetite since one and a half years. FNAC of cervical lymph nodes was done which showed necrotising lymphadenitis. Anti tubercular treatment was thus started but patient defaulted after one month due to intolerance. Though Sputum for mycobacterium was negative but somehow ATT was continued. She also had gingival hyperplasia and rashes on face (fig 2). Routine investigations like complete blood counts, liver and renal function test did not revealed any abnormality. Peripheral Smear showed anisopoikilocytes with microcytic hypochromic picture. Chest X-ray (fig 3) revealed mediastinal widening. Subsequently HRCT (fig 4) revealed bilateral hilar and mediastinal adenopathy. Ultrasound Abdomen showed no organomegaly or paraaortic lymph node enlargement. Serum ACE and Urinary Calcium levels were normal. Mantoux test was positive. During hospitalization patient became hypotensive and comatose. Limbs were flaccid and deep tendon reflexes were absent. There was dribbling of urine without bladder distension and passing motions without awareness. Detailed past history of other diseases and drug intake was inquired. Patient's attendant told she was on phenytoin sodium 300mg since 4 years for generalised tonic clonic seizures. However, she discontinued medical follow up and continued to take the drug. Hence serum Phenytoin levels were done which showed increased levels (32.30). In MRI Brain mild diffuse Cerebellar atrophy was present. Thus, Phenytoin sodium was replaced by levetiracetam. Gradually patient improved and lymphadenopathy regressed on further follow up.

Discussion: Though we make every effort to obtain detailed treatment history of our patients this patient assumed that the consumption of Phenytoin was different from this disease, that's why patient's relatives did not disclose phenytoin consumption in the beginning. This sort of behaviour is sometimes noted in rural patients who often have prejudices of different kinds. Phenytoin use has been associated with various lymph node abnormalities. Lymphadenopathy in association with the use of hydantoin derivatives such as phenytoin was first described in 1940 by Coope and Brown². In 1959, Salzstein and Ackerman³ reviewed 75 cases and reported a further 7 patients, two of whom subsequently died 5 years later due to lymphoma. In 1966, Hymann and Somers⁴ reported 6 patients on anticonvulsant therapy who developed a histologically proven Hodgkins lymphoma or lymphosarcoma. More recent publication divides these occurrences into two, the anticonvulsant hypersensitivity syndrome, and the phenytoin induced pseudo lymphoma. The anticonvulsant hypersensitivity syndrome develops within 8 weeks after the drug is first prescribed. In contrast to hypersensitivity syndrome, phenytoin induced pseudolymphoma is a late effect of phenytoin therapy which can occur years after initiating therapy, as in our case study. In our case study the patient had gingival hyperplasia, gum hypertrophy, rashes on face and cerebellar atrophy as occurs in cases of phenytoin toxicity. Gingival hyperplasia occurs in about 20% of all patients during chronic therapy and is probably the most common manifestation of phenytoin toxicity in children and young adolescent¹. Also there was generalised atonia of all the limbs along with bowel and bladder atonia which hasn't been reported till date. After discontinuing the patient's phenytoin, atonia resolved over few days and gradually the lymphadenopathy regressed.

On conclusion, pathophysiology of phenytoin-induced lymphadenopathy is incompletely understood. It can require careful pathological scrutiny to differentiate it from monoclonal cell expansion. Given the number of patients regularly using phenytoin, it is an important clinical entity that general physicians need to be cognizant of.

REFERENCES:

- [1] Mcnamar J O. Pharmacotherapy of the epilepsies-Chapter 19. In Goodman & Gilman's the Pharmacological Basis of Therapeutics - 11th ed. Editor Brunton L L (2006) Mcgraw-Hill Medical Publishing Division, New York Chicago 2006:
- [2] Coope R, Burrows RGR. Treatment of epilepsy with sodium diphenylhydantoinate. Lancet 1940; i490-2.
- [3] Saltzstein SL, Ackerman LV. Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphomas. Cancer 1959; 12;164-82
- [4] Hyman GA, Sommers SC, the development of Hodgkin's disease and lymphoma during anticonvulsant therapy. Blood 1966; 28; 416-27.
- [5] SG Chong, A O'Brien, BP Casserly et al. An Unusual Cause Of Mediastinal

Lymphadenopathy in priory.com



Fig no:1 –Cervical Lymphadenopathy



Fig No:2Hyperpigmented Skin Rashes on face



Fig No: 3 Mediastinal widening and bilateral infiltrates




Fig No: 4 HRCT thorax showing bilateral hilar and mediastinal adenopathy.